Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid

Expert Review of Proteomics

Volumn 9, Issue 6, 2012, Pages 595-598

  Gjertsen, Bjørn Tore ^a,b   Wiig, Helge ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

acute myeloid leukemia; chemoresistance; chronic myeloid leukemia; interstitial fluid; proteomics; tyrosine kinase inhibitor

Indexed keywords

EID: 85016469279     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.12.55     Document Type: Article

References (17)

1. Hunter T. Treatment for chronic myelogenous leukemia: the long road to imatinib. J. Clin. Invest. 117 (8), 2036 – 2043 (2007).
2. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 112 (13), 4808 – 4817 (2008).
3. Mahon FX, Réa D, Guilhot J et al.; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11 (11), 1029 – 1035 (2010).
4. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J. Clin. Oncol. 29 (5), 475 – 486 (2011).
5. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 29 (5), 487 – 494 (2011).
6. Bruserud Ø, Ryningen A, Olsnes AM et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 92 (3), 332 – 341 (2007).
7. Pizzatti L, Panis C, Lemos G et al. Label-free MS(E) proteomic analysis of chronic myeloid leukemia bone marrow plasma: disclosing new insights from therapy resistance. Proteomics 12 (17), 2618 – 2631 (2012).
8. Tam SW, Pirro J, Hinerfeld D. Depletion and fractionation technologies in plasma proteomic analysis. Expert Rev. Proteomics 1 (4), 411 – 420 (2004).
9. Wiig H, Berggreen E, Borge BA, Iversen PO. Demonstration of altered signaling responses in bone marrow extracellular fluid during increased hematopoiesis in rats using a centrifugation method. Am. J. Physiol. Heart Circ. Physiol. 286 (5), H2028 – H2034 (2004).
10. Gjertsen BT, Bruserud Ø. How should clinical data be included in experimental studies of cancer immunology? Cancer Immunol. Immunother. 53 (8), 677 – 680 (2004).
11. Zhang W, Trachootham D, Liu J et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat. Cell Biol. 14 (3), 276 – 286 (2012).
12. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 328 (6128), 342 – 344 (1987).
13. Weisberg E, Azab AK, Manley PW et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 26 (5), 985 – 990 (2012).
14. Wiig H, Swartz MA. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol. Rev. 92 (3), 1005 – 1060 (2012).
15. Wang W, Gou L, Xie G et al. Proteomic analysis of interstitial fluid in bone marrow identified that peroxiredoxin 2 regulates H(2)O(2) level of bone marrow during aging. J. Proteome Res. 9 (8), 3812 – 3819 (2010).
16. Iversen PO, Wiig H. Tumor necrosis factor alpha and adiponectin in bone marrow interstitial fluid from patients with acute myeloid leukemia inhibit normal hematopoiesis. Clin. Cancer Res. 11 (19 Pt 1), 6793 – 6799 (2005).
17. Wiig H, Tenstad O, Iversen PO, Kalluri R, Bjerkvig R. Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair 3, 12 (2010).